The efficiency and safety of recombinant factor VIIa for bleeding in patients without haemophilia: a meta-analysis of 12 randomized controlled trials

CURRENT STATUS: POSTED

Ying Zhang
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Yuting Wang
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Youfa Zhou
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Jian Li
Wenzhou Medical University

Haiyan Zhou
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

2185031@zju.edu.cn Corresponding Author

DOI: 10.21203/rs.2.18751/v2

SUBJECT AREAS
Anesthesiology & Pain Medicine

KEYWORDS
non-hemophiliac, off-label use, bleeding, recombinant factor VIIa, arterial thrombotic events
Abstract

Background: Despite widely use of recombinant factor VIIa (rFVIIa) for bleeding in patients without haemophilia, its efficiency and safety remain unclear. Therefore, we carried out a meta-analysis on this topic. Methods: We searched Cochrane Library, Web of Science, PubMed and Embase, from January 2008 to July 2019 for randomized controlled trials on the topic. The results of this work are synthesized and reported in accordance with the PRISMA statement. Results: Twelve trials met our inclusion criteria. rFVIIa over 200ug/kg reduced red blood cell (RBC) transfusions within 24 h by 232.34ml (95% confidence interval CI; -410.31 to -54.37). rFVIIa did not significantly reduce 30-day mortality (relative risk RR, 1.00; 95%CI, 0.82-1.21), total thromboembolic events (RR, 1.13; 95%CI, 0.94-1.36), myocardial infarction (RR, 1.37; 95%CI, 0.92-2.05), deep vein thrombosis (RR, 0.83; 95%CI, 0.52-1.33), ICU staying (RR, 0.40; 95%CI, -1.28 to 2.07) and number of patients transfused RBC (RR, 0.94; 95%CI, 0.83-1.08). However, rFVIIa may increase the incidence of arterial thrombotic events (RR, 1.38; 95%CI, 1.08-1.77). Conclusion: rFVIIa over 200ug/kg reduced RBC transfusions for bleeding in patients without haemophilia. However, it may increase the risk of arterial thrombotic events.

Background

Major bleeding is an usually perioperative complication, which not only increases the incidence of homologous blood transfusion but also increases mortality[1,2]. Recombinant activated factor VII (rFVIIa), a potent procoagulant that promotes hemostasis at sites of vascular injury [3]. It is licensed for the treatment of patients with haemophilia A and B, acquired haemophilia, factor VII deficiency, or Glanzmann thrombasthenia, but it has been successfully used off-label in a very large number of patients with major bleeding [4]. Off-label used of rFVIIa has been reported in severe trauma, liver transplantation, cardiac surgery, spontaneous intracerebral haemorrhage (ICH), and postpartum haemorrhage (PPH) [6-16]. A clinical trial published recently in patients with spontaneous intracerebral hemorrhage (ICH) that the administration of rFVIIa limits hematoma expansion [17]. However, concerns about extending the use of rFVIIa is the potential for adverse effects, in particular the risk of thromboembolism [5]. Mayer SA et al. [18] has reported that rFVIIa used to treatment of
acute intracerebral hemorrhage increased thromboembolic. But studies could not show a clear benefit and harmful. Studies considering other systems focused on selected groups of participants or were conducted before many randomized controlled trials (RCT) publications. Therefore, more quality and statistically significant data are needed to guide the off-label applications, new trails are needed to update guidelines to adjust clinical practice. This review will critically evaluate the results of different identification trials and extend the early Cochrane findings for systematic review by including as many additional trials as possible.

Methods

Literature Search and Selection

Four trained investigators independently searched for comprehensive systematic literature in PubMed, Cochrane Library, Embase and Web of Science from January 2008 to July 2019. The search strategy included the following terms: factor VIIa, recombinant activated factor VII, recombinant factor VIIa, NovoSeven, rFVIIa, Factor 7A, Factor Seven A, hemorrhage, bleeding, blood loss, haemorrhage. Moreover, we reviewed the references of included studies and the included research of related reviews to identify additional studies.

This study followed the statement of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [21]. This study analyzed the efficiency and safety of rFVIIa in adult non-haemophiliac hemorrhage in randomized controlled trials. The inclusion criteria were as follows: Patients older than 18 years who require hemostatic treatment for hemorrhage. Patients with haemophilia or other haemostatic defects (for example, Glanzmann’s thrombasthenia, inherited factor VII deficiency) were excluded; intervention: rFVIIa versus (Vs) placebo; study design: randomized controlled trials.

We excluded non-RCT trials and RCT studies in underage patients on this topic. In addition, studies with fewer than 10 patients were excluded, and we think would affect the accuracy and reliability of the analysis results.

Data Extraction and Assessment of Risk of Bias

Retrieved studies were selected by two independent investigators according to inclusion and
exclusion criteria for the final included trials. Data extraction and literature quality assessment were conducted by two researchers separately for the included studies. The baseline details of the included literature were arranged in a table, and the extracted data were recorded in an excel database according to different outcome events. The primary outcome was volume of RBC transfusions with 24h. Secondary outcomes included the 30-day mortality, total thromboembolic events and incidences of patients with myocardial infarction, arterial thrombotic events, deep vein thrombosis, and numbers of patients transfused RBC and ICU-staying. The assessment of the risk of bias was evaluated by the Cochrane risk of bias tool recommended by the Cochrane Collaboration [22]. Two reviewers independently assessed each domain of included studies and any disagreement was resolved by another investigator.

**Statistical Analysis**

The risk ratio (RR) with 95% confidence intervals (95% CIs) was calculated for categorical varies and the mean difference (MD) was estimated by numeric varies. Heterogeneity among studies was tested using the Cochrane Chi-square test and Inconsistency index ($I^2$), in which $I^2 > 50\%$ suggested significant heterogeneity. And when $I^2 > 50\%$, a random-effects model was chosen to pool the results, while the fixed-effects model was used when $I^2 < 50\%$. Publication bias was detected using the Funnel plots tests, and the Egger test was recommended for enumeration data [23]. Two-tailed P-values < 0.05 were considered statistical significance. The effect of publication bias on study results was analysis with the trim and fill method. In order to evaluate the effect of dose on red blood cell transfusions, we added a subgroup analysis to observe whether using a higher dose of rFVIIa can reduce RBC transfusions and improve the hemostatic effect. We performed sensitivity analyses of primary outcome events and heterogeneous significant outcomes. All data analysis was conducted by using ReviewManager (RevMan; version 5.3) and STATA, version 12.0 (Stata Corporation, College Station, TX).

**Results**

**Results of search**

According to the previous search strategy, 617 studies were obtained from the four databases and 2
studies were found by searching the reference lists and reviewed articles. After removing the duplicates, 416 publications remained in total and 401 records were excluded by browsing title and abstract. Among the remaining 15 records, 4 citations were removed according to our inclusion and exclusion criteria. Finally, 11 full-text studies (12 trials, a study consisted of 2 parallel randomized controlled trials) were suitable for this meta-analysis. (Fig. 1). The characteristics, type of haemorrhage and intervention methods of included studies were summarized in Table 1.

**Risk of bias within studies**

Bias risk of twelve trials was assessed in Fig. 2. Two experiments did not provide a detailed method of random processes. The blinding process was at high risk of bias in two studies and unclear risk of bias in one study. No study had unclear or incomplete descriptions of their outcome data. Five trials did not provide a satisfactory description of reporting bias and nine studies did not indicate the other bias in the article.

**Analysis of Primary outcomes**

**Death**

A total of 2,040 patients from nine studies were included in the analysis of 30-day mortality in both rFVIIa and control groups. The results showed that rFVIIa did not increase the incidence of death events from a meta-analysis [220/1217 vs 139/823, RR=1.00 (0.82-1.21), P for effect= 0.98]. No heterogeneity was revealed in the results. [P for heterogeneity =0.83, I² = 0%] (Fig. 3a).

**Total thromboembolic events**

Total thromboembolic events occurred in 279 of 1786 patients in the experimental group and 143 of 1,083 in the control group. rFVIIa did not increase the incidence of total thromboembolic events overall from meta-analysis. [RR=1.13 (0.94-1.36), P for effect= 0.20]. No heterogeneity was revealed in the result. [P for heterogeneity =0.54, I² = 0%] (Fig. 3b).

**RBC transfusions**

Six trials reported the volume of RBC transfusions, with a total of 907 participants. The results showed that there was no significant difference between the two groups [MD = -168.12 (-381.84–45.60), P for effect=0.12]. Heterogeneity was revealed in the result. [P for heterogeneity [0.01][I² = 76%].
Considering the significant heterogeneity of the experimental results, we performed subgroup analysis to compare the volume of red cells transfusion between the low-dose (200ug/kg) and high-dose (200ug/kg) groups. In the subgroup of patients with low-dose, rFVIIa did not significantly reduce RBC transfusion compared with the control group. [MD = -106.72(-448.33–234.89), P for effect =0.54, P for heterogeneity< 0.0001, I² = 90%]. In the subgroup of patients with high-dose, rFVIIa significantly reduced RBC transfusion. [MD=-232.34(-410.31–-54.37), P for effect =0.01, P for heterogeneity=0.77, I² = 0%]. (Fig.3c).

**Analysis of Second outcomes**

**Arterial thrombotic events**

Compared with the control group, rFVIIa significantly increased the incidence of arterial thrombotic events, and there was no significant heterogeneity. [RR = 1.38(1.08–1.77), P for effect =0.01, P for heterogeneity=0.87, I² = 0%]. (Fig.4a)

**Myocardial infarction**

In total, 8 studies with 2295 participants reported the incidence of myocardial infarctions after using rFVIIa and placebo. The overall analysis showed no increased risk of myocardial infarction [86/1508 vs 30/787, RR =1.37 (0.92–2.05), P for effect = 0.13, P for heterogeneity =0.43, I² = 0%]. (Fig.4b)

**Deep vein thrombosis**

Seven studies reported the incidence of deep vein thrombosis in this meta-analysis. The RR for deep vein thrombosis (DVT) with the use of rFVIIa versus placebo was 0.83 (95% CI 0.51–1.33) which suggested that rFVIIa would not increase the incidence of DVT. No heterogeneity was revealed in the result. [P for heterogeneity =0.59, I² = 0%] (Fig. 4c).

**Number of patients transfused RBC**

Number of patients transfused RBC in the rFVIIa group and the control group was 414/497 and 378/433, respectively. rFVIIa did not reduce the number of patients transfused RBC overall from meta-analysis. [RR =0.94 (0.83–1.08), P for effect = 0.39, P for heterogeneity =0.002, I² = 77%]. (Fig.5a).

**ICU-staying**
Four trails with a total of 627 participants reported the ICU-stay days. Overall, rFVIIa did not significantly reduce length of ICU-stay. [RR = 0.40(-1.28–2.07), P for effect=0.64, P for heterogeneity=0.77, $I^2 = 0\%$] (Fig. 5b).

**Publication Bias and Sensitivity Analysis**

Funnel plots showed that there was asymmetric distribution of included studies. Egger tests and trims and fill method demonstrated that there was no publication bias in all the studies. Sensitivity analyses have confirmed that all results are robust. All the results were shown in the Supplementary Figures.

**Discussion**

The main results in this meta-analyzed show that high dose rFVIIa would significantly reduce RBC transfusions, increase arterial thrombotic events, but did not increase patiences mortality, ICU-stay, total thromboembolic events, deep vein thrombosis and myocardial infarction.

All of the included studies were randomized controlled trials, included cardiac surgery[15,18,22], intracerebral hemorrhage[14,19,21,23], postpartum haemorrhage[16], severe acute pancreatitis[17], trauma[20] and upper gastrointestinal haemorrhage[24]. Besides, there were no heterogeneity among studies on most outcomes and sensitivity analysis also suggested the results were not affected by individual research.

Our study contains 12 trials with 2928 patients (1218 patients in control group Vs 1710 patients in treatment group) and reflects the latest results for the treatment of rFVIIa. rFVIIa over 200ug/kg reduced RBC transfusions within 24 h. rFVIIa did not significantly affect 30-day mortality, total thromboembolic events, myocardial infarction, deep vein thrombosis, ICU-stay and number of patients transfused RBC. However, rFVIIa may increase the incidence of arterial thrombotic events.

Similar to the previous studies, our meta-analysis suggested that rFVIIadid not increase mortality and total thromboembolic events [20]. Compared with previous studies, we analyzed the effects of rFVIIa on different thrombotic events in more detail and performed a subgroup analysis of RBC transfusions. Guidelines recommend different dosage for different patient cohorts. We found that the single-use dose of rFVIIa did not exceed 200ug/kg, and the multiple-use dose exceeded 200ug/kg. Therefore, we set a cut-off point at 200ug/kg. In this experiment, we found that rFVIIa over 200ug/kg reduced RBC
transfusions. Besides, we added a comparison of outcome events such as myocardial infarction, deep vein thrombosis, and ICU-stay. There was no statistical difference between the two groups.

We acknowledge some potential limitations in this study. Firstly, heterogeneity due to clinical and methodological diversity was inevitable which may affect the reliability of the analysis results especially in meta-analyses of transfusion. Secondly, we used different measurement units for conversion, which may affect the reliability of the experimental results. In the future, we hope to have more large-scale randomized controlled experiments to research this topic.

**Conclusion**

The current study systematically reviewed the existing evidence on the efficacy and safety profile of rFVIIa in patients without haemophilia. The results show that high dose rFVIIa would significantly reduce RBC transfusions. rFVIIa did not increase mortality, ICU-stay, total thromboembolic events, deep vein thrombosis and myocardial infarction. However, rFVIIa increased arterial thrombotic events. Overall, further studies are needed to identify the optimal dose and regime for intravenous use of rFVIIa to achieve the best benefit with the lowest risk.

**Abbreviations**

rFVIIa: Recombinant human factor VIIa

RCT: randomized controlled trials

RR: risk ratio

CI: confidence intervals

MD: mean difference

I²: Inconsistency index

Vs: versus

**Declarations**

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials
All data generated or analysed during this study are included in this published article and its supplementary information files.

Competing interests
The authors declare that they have no competing interests.

Funding
This work was supported by the medical and health science and technology project of Zhejiang in writing and reviewing of manuscript. (Grant No. 2019RC044).

Author’s contributions
YZ, JL and HYZ were involved in the study design, data review, data analysis, writing paper, review and approval of final manuscript. YTW, YFZ and HYZ were involved in data review, data analysis, review and approval of final manuscript. All authors read and approved the final manuscript.

Acknowledgements
Not applicable

References
1. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356:2301-2311.

2. Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion. 2004;44:1453-1462.

3. Janet B, Simon J. Stanworth, et al. Evidence for the Use of Recombinant Factor VIIa in the Prevention and Treatment of Bleeding in Patients Without Hemophilia. Transfusion Medicine Reviews, Vol 22, No 3 (July), 2008: pp 177-187

4. Levi M, Schultz M. Coagulopathy and platelets disorders in critically ill patients. Minerva Anestesiol2010;76:851-9.

5. Karkouti K, Beattie WS, Wijeysundera DN, Yau TM, McCluskey SA, Ghannam M, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: A propensityscore-matched case-control analysis. Transfusion. 2005;45:26-34
6. David JG, Richard IA, Andrew MD, et al. Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign–Positive Acute Intracerebral Hemorrhage The SPOTLIGHT and STOP-IT Randomized Clinical Trials. JAMA Neurology. August 19, 2019

7. Narges P, Mahnoosh F, Ali D. The Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial. Anesth Pain Med. 2015 February; 5(1): e22846.

8. Lavigne-Lissalde G, Aya AG, Mercier FJ, et al. Recombinant human FVIIa for reducing the need of invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J ThrombHaemost 2015;13: 520–9

9. Jun Lu, Lian-mingLiao , Yan-xiaGeng, et al. A double-blind, randomized, controlled study to explore the efficacy of rFVIIa on intraoperative blood loss and mortality in patients with severe acute pancreatitis. Thrombosis Research 133 (2014) 574-578

10. Mohamed Essam Abdel- Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery. Saudi Journal of Anaesthesia. Vol. 7, Issue 3, July-September 2013

11. IMBERTI, L. PIETROBONO, C. KLERSY, et al. Intraoperative intravenous administration of rFVIIa and hematoma volume after early surgery for spontaneous intracerebral hemorrhage: a randomized prospective phase II study. MINERVA ANESTESIOLOGICA 2012 Vol. 78 - No. 2 168-175

12. Carl J. Hauser, Kenneth Boffard, Richard Dutton, et al. Results of the CONTROL Trial: Efficacy and Safety of Recombinant Activated Factor VII in the Management of Refractory Traumatic Hemorrhage. J Trauma. 2010;69: 489-500

13. Michael ND, Brett ES, Stephan AM, et al. Thromboembolic Events With Recombinant
Activated Factor VII in Spontaneous Intracerebral Hemorrhage Results From the Factor Seven for Acute Hemorrhagic Stroke (FAST) Trial. Stroke. 2010;41:48-53

14. Ravi Gill, BM, Mike H, Alain V, et al. Safety and Efficacy of Recombinant Activated Factor VII A Randomized Placebo-Controlled Trial in the Setting of Bleeding After Cardiac Surgery. Circulation. 2009;120:21-27.

15. Stephan AM, Nikolai CB, Kamilla B, et al. Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage. N Engl J Med 2008;358:2127-37

16. Jaime Bosch, Dominique Thabut, Agustí´nAlbillos, et al. Recombinant Factor VIIa for Variceal Bleeding in Patients with Advanced Cirrhosis: a Randomized, Controlled Trial. HEPATOLOGY 2008;47:1604-1614.

17. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN et al. Recombinant activated factor VII for acuteintracerebral hemorrhage. N Engl J Med 2005;352:777-85.

18. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N EnglJ Med. 2008;358:2127-37.

19. Habib AM. Comparison of low- and high-dose recombinant activated factor VII for postcardiac surgical bleeding. Indian J Crit Care Med 2016;20:497-503.

20. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No.: CD005011. DOI: 10.1002/14651858.CD005011.pub4.

21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol.
2009;62:1006–12.

22. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928

23. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.

Table
Table 1 Characteristics of included studies

| Study ID       | Country                        | No. C/T | Sex F/M | Type of hemorrhage                  |
|----------------|--------------------------------|---------|---------|-------------------------------------|
| Gladstone 2019 [6] | Canada                        | 37/32   | 34/35   | Acute Intracerebral Hemorrhage     |
| Payani 2015 [7]      | Iran                          | 18/18   | 12/24   | Cardiac Valve Reoperations        |
| Lavigne-Lissalde 2015 [8] | Switzerland and France | 42/42   | 84/0    | Severe Refractory Postpartum Hemorrhage |
| Lu 2014 [9]            | China                         | 33/31   | 20/44   | Severe Acute Pancreatitis         |
| Abdel-Meguid 2013 [10] | Saudi Arabia                  | 15/15   | NA      | Coronary Revascularization Surgery under CPB |
| Imberti 2012 [11]     | Italy                         | 8/13    | 5/16    | Spontaneous Intracerebral Hemorrhage |
| Hauser 2010a [12]      | 26 countries                  | 247/221 | NA      | Blunt Trauma                      |
| Study                | Countries | Mortality Rate | Cause of Death | Disease                        |
|---------------------|-----------|----------------|----------------|--------------------------------|
| Hauser 2010b [12]   | 26 countries | 40/46          | NA             | Penetrating Trauma             |
| Diringer 2010 [13]  | 22 countries | 558/263        | 322/519        | Spontaneous Intracerebral Hemorrhage |
| Gill 2009 [14]      | 13 countries | 68/104         | 44/128         | Cardiac Surgery Requiring CPB   |
| Mayer 2008 [15]     | 22 countries | 558/263        | 322/519        | Spontaneous Intracerebral Hemorrhage |
| Bosch 2008 [16]     | 12 countries | 86/170         | 69/187         | Upper Gastrointestinal Haemorrhage |

**Figures**
Figure 1
Flow diagram of the literature strategy
Figure 2 A. risk-of-bias summary; B. risk-of-bias graph for all the included randomized-controlled trials
### Figure 3

Forest plot of meta-analysis in primary outcomes.

| Study or Subgroup | rFVIIa | Placebo | Risk Ratio |
|-------------------|--------|---------|------------|
| Events Total      | Events Total | Weight | M-H Fixed, 95% CI | M-H Fixed, 95% CI |
| Bosch 2008        | 9     | 26     | 20.1% | 0.79 [0.65, 1.01] |
| Gille 2006        | 10    | 4      | 2.9%  | 1.63 [0.58, 4.73] |
| Gladstone 2019    | 9     | 13     | 7.4%  | 1.78 [0.59, 5.79] |
| Hauser 2010a      | 30    | 224    | 18.9% | 1.01 [0.64, 1.61] |
| Hauser 2010b      | 9     | 40     | 3.2%  | 1.57 [0.58, 4.29] |
| Imbert 2012       | 7     | 5      | 3.1%  | 0.89 [0.41, 1.93] |
| Lavoie-Lisse 2015 | 0     | 42     | Not estimable |
| Lu 2014           | 4     | 33     | 1.6%  | 1.42 [0.35, 5.84] |
| Mayor 2008        | 112   | 252    | 42.0% | 1.03 [0.77, 1.39] |
| Total (95% CI)    | 1217  | 823    | 160.0% | 1.00 [0.62, 1.21] |

Heterogeneity: Chi² = 3.87, df = 7 (P = 0.83); I² = 0%
Test for overall effect: Z = 0.03 (P = 0.98)

---

| Study or Subgroup | rFVIIa | Placebo | Risk Ratio |
|-------------------|--------|---------|------------|
| Events Total      | Events Total | Weight | M-H Fixed, 95% CI | M-H Fixed, 95% CI |
| Bosch 2008        | 9     | 26     | 5.3%  | 0.65 [0.25, 1.76] |
| Döhrer 2016       | 159   | 66     | 51.1% | 1.13 [0.88, 1.46] |
| Gille 2009        | 7     | 1     | 0.7%  | 4.58 [0.59, 35.39] |
| Gladstone 2019    | 4     | 6      | 4.2%  | 0.58 [0.19, 1.74] |
| Hauser 2010a      | 36    | 33     | 17.7% | 1.22 [0.75, 1.89] |
| Hauser 2010b      | 2     | 4      | 2.4%  | 0.43 [0.08, 2.25] |
| Imbert 2012       | 5     | 3      | 2.1%  | 1.03 [0.33, 3.17] |
| Lavoie-Lisse 2015 | 2     | 0      | 0.3%  | 5.00 [0.25, 101.1] |
| Mayor 2008        | 55    | 21     | 16.2% | 1.24 [0.76, 2.03] |
| Payares 2015      | 0     | 0      | Not estimable |
| Total (95% CI)    | 1786  | 1093   | 160.0% | 1.13 [0.54, 2.36] |

Heterogeneity: Chi² = 6.06, df = 8 (P = 0.54); I² = 0%
Test for overall effect: Z = 1.28 (P = 0.20)

---

| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Mean Difference | IV, Random, 95% CI |
|-------------------|------|---|-------|------|---|-------|-----------------|-------------------|
| 1.1.1 Total dose <200 µ/kg | 110 | 43 | 110 | 111 | 43 | 111 | 22.0% | 209.00 [91.12, 396.98] |
| 1.1.2 Total dose >200 µ/kg | 480 | 273 | 480 | 481 | 273 | 481 | 22.1% | 210.00 [99.21, 320.76] |

Heterogeneity: Tau² = 94.89, Chi² = 152.96, df = 2 (P = 0.0001), I² = 50%
Test for overall effect: Z = 0.61 (P = 0.54)

---

Fig 3 Forest plot of meta-analysis in primary outcomes.
A. death B. total thromboembolic events C. red cell transfusion (ml)
| Study or Subgroup | rFVIIa | Placebo | Risk Ratio | Risk Ratio |
|-------------------|--------|---------|------------|------------|
|                   | Events | Total   | Events | Total | Weight | M-H Fixed, 95% CI | M-H Fixed, 95% CI |
| Bosch 2008        | 3      | 176     | 0      | 89    | 0.7%   | 3.56 [0.19, 68.16] |
| Diringer 2010     | 129    | 573     | 49     | 268   | 70.2%  | 1.23 [0.92, 1.65] |
| Gils 2009         | 4      | 104     | 1      | 66    | 1.3%   | 2.62 [0.30, 22.90] |
| Hauser 2010a      | 16     | 224     | 11     | 250   | 10.9%  | 1.62 [0.77, 3.42] |
| Hauser 2010b      | 2      | 46      | 1      | 40    | 1.1%   | 1.74 [0.16, 18.47] |
| Mayer 2008        | 39     | 558     | 11     | 263   | 15.7%  | 1.67 [0.87, 3.21] |

Total (95% CI) 1681 978 100.0% 1.38 [1.08, 1.77]

Total events 153 73

Heterogeneity: $I^2 = 18.6$, $df = 5$ ($P = 0.67$); $H^2 = 0$
Test for overall effect: $Z = 2.55$ ($P = 0.01$)

---

**Figure 4** Forest plot of meta-analysis in second outcomes.
A. arterial events B. myocardial infarction C. deep vein thrombosis
Figure 5

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

Fig S2.pdf
PRISMA 2009 checklist.doc
Fig S1.pdf
Fig S3.pdf